Evidence map›Paper›PMID 41918761›Full record

ArticleNew microbes and new infections2026

Resilience and residuals beyond containment - The hidden burden of Bundibugyo Ebola virus survivorship sixteen years on: A cross-sectional observational study.

Raymond Ernest Kaweesa, Joseph Ssebwana Katende, Raymond Reuel Wayesu, Annie Daphine Ntabadde, Solomon Opio, Laban Kato, Gerald Kevin Oluka, Ruth Nambi, Rodney Abraham Tumusiime, FiloStudy Team and 3 more

Abstract read
In one paragraph

Article in New microbes and new infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Raymond Ernest KaweesaDepartment of Immunology, Uganda Virus Research Institute, Entebbe, Uganda.
Joseph Ssebwana KatendeDepartment of Immunology, Uganda Virus Research Institute, Entebbe, Uganda.
Raymond Reuel WayesuDepartment of Immunology, Uganda Virus Research Institute, Entebbe, Uganda.
Annie Daphine NtabaddeDepartment of Immunology, Uganda Virus Research Institute, Entebbe, Uganda.
Solomon OpioUganda Virus Research Institute and London School of Hygiene & Tropical Medicine (MRC/UVRI & LSHTM) Uganda Research Unit, Entebbe, Uganda.
Laban KatoUganda Virus Research Institute and London School of Hygiene & Tropical Medicine (MRC/UVRI & LSHTM) Uganda Research Unit, Entebbe, Uganda.
Gerald Kevin OlukaDepartment of Immunology, Uganda Virus Research Institute, Entebbe, Uganda.
Ruth NambiDepartment of Immunology, Uganda Virus Research Institute, Entebbe, Uganda.
Rodney Abraham TumusiimeDepartment of Immunology, Uganda Virus Research Institute, Entebbe, Uganda.
FiloStudy Team
Pontiano KaleebuDepartment of Immunology, Uganda Virus Research Institute, Entebbe, Uganda.
Julius Julian LutwamaDepartment of Immunology, Uganda Virus Research Institute, Entebbe, Uganda.
Jennifer SerwangaDepartment of Immunology, Uganda Virus Research Institute, Entebbe, Uganda.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Long-term effects of Ebola disease (EBOD) are well documented for Ebolavirus (EBOV), but limited data exist for Bundibugyo virus disease (BVD) caused by Bundibugyo Ebola virus (BDBV), a genetically distinct strain. Methods: We conducted a cross-sectional observational study involving 40 laboratory-confirmed BVD survivors and 23 age- and sex-matched unexposed community controls to evaluate the long-term clinical, biochemical, immunological, and psychosocial sequelae associated with BDBV infection. Participants underwent comprehensive clinical evaluations, laboratory testing, and standardised mental health assessments. Statistical comparisons used rank-sum, chi-squared, and correlation analyses. Findings: Survivors exhibited persistent multisystem symptoms, with neurological and musculoskeletal complaints most frequent, headaches (35 %) and visual disturbances (22.5 %). Laboratory findings showed elevated basophils (40 %) and urinary ketones (5 %), indicating possible chronic inflammation and metabolic shifts. Respiratory rates were significantly reduced in survivors (p < 0.001), while other vital signs and biochemical markers were largely within normal ranges. Despite high resilience, 70 % with normal anxiety scores and 62.5 % with normal depression scores, 57.5 % reported persistent stigma. Survivors also exhibited unique physiological correlations, suggestive of post-infectious homeostatic changes. Conclusion: BVD survivors experience long-term multisystem sequelae and physiological remodeling. These findings support the need for virus-specific post-BVD care and sustained follow-up to inform survivor health policy.

Indexed as

Bundibugyo ebolavirusEbola disease (EBOD) survivorsEpidemic preparednessImmunometabolic findingsLong-term viral sequelaePost-ebola syndromeSurvivorship care models

Identifiers

PMID41918761
PMCPMC13033831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.